eFFECTOR's Tomiversib Flops In Lung Cancer, Hopes Rest On AML
The company still sees a potential path forward for tomivosertib in acute myeloid leukemia, where its mechanistic rationale is distinct from the one in NSCLC.
The company still sees a potential path forward for tomivosertib in acute myeloid leukemia, where its mechanistic rationale is distinct from the one in NSCLC.